Clinical trials: Recurrent Malignant Mesothelioma
Malignant Mesothelioma, Metastatic Cancer
Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma
RATIONALE: Video-assisted surgery to remove part of the tissue layer covering the inside of the chest cavity may be effective in treating pleural effusion and cause less damage to normal tissue.
- Trial name
- MesoVATS (NCT00821860)
- Testing
- talc, therapeutic thoracoscopy, therapeutic videothoracoscopy
- Where
- 5 sites in United Kingdom
- Volunteers
- 196 people
- Sponsor
- Papworth Hospital NHS Foundation Trust
Peritoneal Mesothelioma, Fallopian Tube Adenocarcinoma
Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma
This is a phase 1 dose escalation study to characterize the feasibility, safety and tolerability of MCY-M11 when administered as an intraperitoneal (IP) infusion for 3 weekly doses for women with platinum resistant high grade…
- Conditions
- Peritoneal Mesothelioma, Fallopian Tube Adenocarcinoma, Adenocarcinoma of the Ovary, Primary Peritoneal Carcinoma
- Trial name
- NCT03608618
- Testing
- MCY-M11, Cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- MaxCyte, Inc.
Mesothelioma, Malignant
Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma
MiST is a British Lung Foundation funded, University of Leicester Study, a multi-arm stratified therapy based clinical trial for patients with relapsed mesothelioma.
- Trial name
- MiST (NCT03654833)
- Testing
- Rucaparib, Abemaciclib, pembrolizumab & bemcentinib
- Where
- United Kingdom
- Volunteers
- 186 people
- Sponsor
- University of Leicester
Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer
CT-95 in Advanced Cancers Associated With Mesothelin Expression
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with…
- Conditions
- Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced
- Trial name
- NCT06756035
- Testing
- CT-95
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- Context Therapeutics Inc.
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC)
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine…
- Conditions
- NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus
- Trial name
- NCT07277413
- Testing
- IDE892, IDE397
- Where
- 23 sites in United States
- Volunteers
- 260 people
- Sponsor
- IDEAYA Biosciences
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Epithelioid Mesothelioma, Recurrent Malignant Mesothelioma
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
This phase II trial studies how well tivantinib works in treating patients with previously treated malignant mesothelioma. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Epithelioid Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatoid Mesothelioma, Stage II Pleural Mesothelioma
- Trial name
- NCT01861301
- Testing
- Laboratory Biomarker Analysis, Tivantinib
- Where
- 18 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Solid Organ Tumors
A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study
The purpose of this research study is to collect information from patient's medical records that had a test called ChemoFx® ordered and to understand how doctors may have used the results of the ChemoFx® to treat patients with…
- Trial name
- NCT01271959
- Where
- 25 sites in United States
- Volunteers
- 167 people
- Sponsor
- Precision Therapeutics
Lung Cancer, Malignant Mesothelioma
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer.
- Conditions
- Lung Cancer, Malignant Mesothelioma, Metastatic Cancer, Thymoma and Thymic Carcinoma
- Trial name
- NCT00024076
- Testing
- radiofrequency ablation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Malignant Mesothelioma
Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of raltitrexed in treating patients who have malignant…
- Trial name
- NCT00004254
- Testing
- raltitrexed
- Where
- 6 sites in Italy, Netherlands
- Volunteers
- 25 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Recurrent Pleural Malignant Mesothelioma, Stage IV Pleural Mesothelioma
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
This phase II trial studies how well nintedanib works in treating patients with malignant pleural mesothelioma that has come back.
- Trial name
- NCT02568449
- Testing
- Nintedanib
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Cancer
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00904514
- Testing
- gene expression analysis, microarray analysis, mutation analysis
- Volunteers
- 241 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Ovarian Cancer, Cholangiocarcinoma Recurrent
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer…
- Conditions
- Ovarian Cancer, Cholangiocarcinoma Recurrent, Mesothelioma, Malignant
- Trial name
- NCT05568680
- Testing
- SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR
- Where
- 5 sites in United States
- Volunteers
- 42 people
- Sponsor
- Verismo Therapeutics
Advanced Malignant Mesothelioma, Epithelial Mesothelioma
Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung
Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. This phase II trial is studying how well erlotinib works in treating patients with malignant mesothelioma of the lung
- Conditions
- Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
- Trial name
- NCT00039182
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Mesothelioma
Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00458913
- Testing
- bortezomib, cisplatin
- Where
- United Kingdom
- Volunteers
- 82 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Recurrent Malignant Mesothelioma, Stage IA Malignant Mesothelioma
Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma
This phase I clinical trial investigates the side effects and the best dose of local (intrapleural measles virus therapy in treating patients with malignant pleural mesothelioma (MPM).
- Conditions
- Recurrent Malignant Mesothelioma, Stage IA Malignant Mesothelioma, Stage IB Malignant Mesothelioma, Stage II Malignant Mesothelioma
- Trial name
- NCT01503177
- Testing
- oncolytic measles virus encoding thyroidal sodium iodide symporter, laboratory biomarker analysis, single photon emission computed tomography
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Malignant Mesothelioma
Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma
The purpose of this study is to determine the response rate to the combination of doxorubicin and valproate acid in patients with MM failing after at least one previous chemotherapy regimen including platinum derivatives .
- Trial name
- NCT00634205
- Testing
- Valproate plus doxorubicin
- Where
- 8 sites in Belgium, France
- Volunteers
- 45 people
- Sponsor
- European Lung Cancer Working Party
Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma, Phase 2 Portion : Small Cell Lung Cancer(SCLC)
Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer
This Phase 1/2 study is designed to assess the following: safety and tolerability of BIW-8962, Dose Limiting Toxicities (DLTs), Maximum Tolerated Dose (MTD), Recommended Phase 2 Dose (RP2D) in Phase 1 in subjects with…
- Trial name
- NCT01898156
- Testing
- BIW-8962
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Kyowa Kirin Korea Co., Ltd.
Esophageal Cancer, Lung Cancer
Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of decitabine in treating patients who have unresectable…
- Conditions
- Esophageal Cancer, Lung Cancer, Malignant Mesothelioma, Metastatic Cancer
- Trial name
- NCT00019825
- Testing
- decitabine
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Advanced Pleural Malignant Mesothelioma, HLA-A*0201 Positive Cells Present
Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
This phase I/II trial studies the side effects and best dose of genetically modified T cells in treating patients with stage III-IV non-small cell lung cancer (NSCLC) or mesothelioma.
- Conditions
- Advanced Pleural Malignant Mesothelioma, HLA-A*0201 Positive Cells Present, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Pleural Malignant Mesothelioma
- Trial name
- NCT02408016
- Testing
- Aldesleukin, Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes, Cyclophosphamide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Fred Hutchinson Cancer Center